These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15582269)
1. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002-2021. Hunter DJ; Drake SM; Shortt SE; Dorland JL; Tran N Cancer Detect Prev; 2004; 28(6):453-60. PubMed ID: 15582269 [TBL] [Abstract][Full Text] [Related]
2. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004. Ekwueme DU; Gardner JG; Subramanian S; Tangka FK; Bapat B; Richardson LC Cancer; 2008 Feb; 112(3):626-35. PubMed ID: 18157831 [TBL] [Abstract][Full Text] [Related]
3. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864 [TBL] [Abstract][Full Text] [Related]
4. A workplace breast cancer screening program. Costs and components. Schrammel P; Griffiths RI; Griffiths CB AAOHN J; 1998 Nov; 46(11):523-9. PubMed ID: 9934000 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697 [TBL] [Abstract][Full Text] [Related]
6. Developing and testing a cost-assessment tool for cancer screening programs. Subramanian S; Ekwueme DU; Gardner JG; Trogdon J Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160 [TBL] [Abstract][Full Text] [Related]
7. Estimating personal costs incurred by a woman participating in mammography screening in the National Breast and Cervical Cancer Early Detection Program. Ekwueme DU; Hall IJ; Richardson LC; Gardner JG; Royalty J; Thompson TD Cancer; 2008 Aug; 113(3):592-601. PubMed ID: 18536027 [TBL] [Abstract][Full Text] [Related]
8. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004 [TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Dewilde S; Anderson R Med Decis Making; 2004; 24(5):486-92. PubMed ID: 15358997 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Anderson BO; Shyyan R; Eniu A; Smith RA; Yip CH; Bese NS; Chow LW; Masood S; Ramsey SD; Carlson RW Breast J; 2006; 12 Suppl 1():S3-15. PubMed ID: 16430397 [TBL] [Abstract][Full Text] [Related]
11. Influence of physician and patient characteristics on adherence to breast cancer screening recommendations. Abdel-Malek N; Chiarelli AM; Sloan M; Stewart DE; Mai V; Howlett RI Eur J Cancer Prev; 2008 Feb; 17(1):48-53. PubMed ID: 18090910 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a community-based intervention to enhance breast cancer screening practices in Brazil. Thuler LC; Freitas HG J Eval Clin Pract; 2008 Dec; 14(6):1012-7. PubMed ID: 18759754 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? Anderson R; Haas M; Shanahan M Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317 [TBL] [Abstract][Full Text] [Related]
15. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993 [TBL] [Abstract][Full Text] [Related]
17. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Siebert U; Sroczynski G; Hillemanns P; Engel J; Stabenow R; Stegmaier C; Voigt K; Gibis B; Hölzel D; Goldie SJ Eur J Public Health; 2006 Apr; 16(2):185-92. PubMed ID: 16469759 [TBL] [Abstract][Full Text] [Related]
18. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. Plevritis SK; Sigal BM; Salzman P; Rosenberg J; Glynn P J Natl Cancer Inst Monogr; 2006; (36):86-95. PubMed ID: 17032898 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
20. [A study on scheduling periodic examinations for the early detection of breast cancer in Korea]. Jeong SH; Kang DR; Hur NW; Kim J; Lee SY; Jung SH; Nam CM J Prev Med Public Health; 2006 Jul; 39(4):346-52. PubMed ID: 16910309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]